These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15237382)

  • 1. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.
    Vogel M; Voigt E; Michaelis HC; Sudhop T; Wolff M; Türler A; Sauerbruch T; Rockstroh JK; Spengler U
    Liver Transpl; 2004 Jul; 10(7):939-44. PubMed ID: 15237382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.
    Jain AB; Venkataramanan R; Eghtesad B; Marcos A; Ragni M; Shapiro R; Rafail AB; Fung JJ
    Liver Transpl; 2003 Sep; 9(9):954-60. PubMed ID: 12942457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
    Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
    AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation.
    Schonder KS; Shullo MA; Okusanya O
    Ann Pharmacother; 2003 Dec; 37(12):1793-6. PubMed ID: 14632538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
    Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of lopinavir/ritonavir for the treatment of HIV-infection.
    Vogel M; Rockstroh JK
    Expert Opin Drug Saf; 2005 May; 4(3):403-20. PubMed ID: 15934849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation.
    Teicher E; Abbara C; Duclos-Vallée JC; Antonini T; Bonhomme-Faivre L; Desbois D; Samuel D; Vittecoq D
    Liver Transpl; 2009 Oct; 15(10):1336-42. PubMed ID: 19790146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.